At this stage, based on our functional assay, we may conclude with caution that therapeutic approaches increasing BTLA expression in T lymphocytes might contribute to undesirable changes in the microenvironment of leukemic B cells, hence promoting CLL progression, which could be an unfavorable strategy for CLL patients. The gene discussed is BTLA; the disease is B-cell chronic lymphocytic leukemia.